Skip to Main content Skip to Navigation
Journal articles

68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT : impact on therapeutic decision-making and biomarker changes

Abstract : Aim/Introduction: The aim of this retrospective study was to investigate the impact of 68Ga-PSMA-11 PET/CT on current management of recurrence prostate cancer patients with negative PET/CT F-Choline. Materials and Methods: Eightynine patients with previously negative 18F-Choline (FCH) were enrolled (PSA from 0.28 to 24.6 ng/mL). PET images were recorded 1 hour after injection of 150 MBq of 68Ga-PSMA. Referring patient physician was asked about the care before and after PSMA PET imaging to determine the influence of PSMA results on therapeutic strategy. Six months after the end of treatment, a PSA assay was requested to evaluate therapeutic efficacy. Results: Sixty-nine among the 89 patients (77,5%) had a positive PSMA PET/CT. Detection rates were 85.6% and 89.4% for serum PSA levels lower than 2 ng/ml, and > 2 ng/ml, respectively. Three hundred and one lesions were detected: 235/301 in lymph nodes (78.1%), 38/301 as metastatic sites (bone, mostly on axial skeleton, or lung) (12.6%) and 28/301 in the prostate bed (9.3%). The majority of lesions were detected in lymph nodes: in particular with 71.5% pelvic nodes, on the other hand with 17.9% of para-aortic nodes and 10.6% with sus diaphragmatic location. For the para-aortic and subdiaphragmatic node locations, initial surgical management associated with pelvic salvage radiotherapy were the most common initial management which could explain the frequently supra-pelvic node recurrence. The median number of lesions per patient was 2 [ranging from 0 to 67]. No particularity of the PSA serum level, doubling time or PSA velocity at the time of PSMA PET-CT could explain why 68Ga-PSMA PET-CT was unable to detect any suspicious tumor lesions in 20 patients. Thanks to PSMA PET/CT, therapeutic management changed in 59/69 patients (84.9%). With a follow-up of 5.7 ± 1.8 months, 62/89 (69.6%) PSA assays after treatment guided by PSMA PET-CT were collected. For 43.5% (27/62) of patients, the serum PSA level was lower than 0.2 ng/mL and a total PSA decrease of over 50% in 35 (56.5%) patients was obtained. Conclusion: Performing a PSMA PET-CT when FCH PET-CT was negative allows the recurrence localization in more 80% of patients and this had a major clinical impact, as it resulted in treatment change in more than 80% of patients as well as a significant decrease in PSA levels in more than 55% of them. References: None.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02337759
Contributor : Elizabeth Bernardo <>
Submitted on : Tuesday, October 29, 2019 - 4:03:37 PM
Last modification on : Thursday, June 18, 2020 - 10:32:04 PM
Document(s) archivé(s) le : Thursday, January 30, 2020 - 9:40:05 PM

File

OP-109 EANM2019.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : inserm-02337759, version 1

Collections

Citation

Caroline Rousseau, A. Michaud, M. Barbaud, C. Morvant, B. Maucherat, et al.. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT : impact on therapeutic decision-making and biomarker changes. European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, 46 (1), pp.S49. ⟨inserm-02337759⟩

Share

Metrics

Record views

53

Files downloads

83